Abstract: A water tank is provided for communicating with a cleaning system on a base station body of a base station and outside of the base station. The water tank includes a clean water cavity configured to hold clean water, a clean water input channel configured to be communicated with the clean water cavity and an external water source outside the base station, a clean water output channel configured to be communicated with the clean water cavity and the cleaning system on the base station body, a sewage cavity configured to hold sewage, a sewage input channel configured to be communicated with the cleaning system on the base station body and the sewage cavity, and a sewage output channel configured to be communicated with the sewage cavity and outside of the base station.

Abstract: The present disclosure provides a pixel driving circuit and a display panel. The pixel drive circuit includes: a data writing sub-circuit, a threshold compensation sub-circuit, a driving sub-circuit and a storage sub-circuit, the data writing sub-circuit includes a fourth transistor, which includes a first electrode connected with a data line, a second electrode connected with a first terminal of the driving sub-circuit, and a control electrode connected with a first scan signal line, and the fourth transistor is an oxide thin film transistor; the threshold compensation sub-circuit is configured to compensate a threshold voltage of the driving sub-circuit in response to a second scan signal; the storage sub-circuit is configured to store a data voltage signal; the driving sub-circuit is configured to provide a driving current for a light emitting device to be driven according to voltages of the first terminal and a control terminal thereof.

Abstract: This document provides methods and materials related to determining whether or not a mammal (e.g., a human) has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or amyotrophic lateral sclerosis (ALS)). For example, methods and materials for using the levels of TDP-43 polypeptides and/or TDP-43 polypeptide cleavage products (e.g., 25 kD and 35 kD TDP-43 polypeptide cleavage products) in a biological fluid (e.g., cerebrospinal fluid) to determine whether or not a mammal has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or ALS) are provided.